NCT02413008 - A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2015

Primary Completion Date

February 10, 2017

Study Completion Date

February 10, 2017

Conditions

Vaginal Atrophy

Interventions

DRUG

estriol

0.005% estriol vaginal gel

DRUG

Placebo

placebo vaginal gel

Trial Locations (6)

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., A Coruña

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Jaén

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Madrid

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Valencia

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., L'Hospitalet de Llobregat

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., Stockholm

All Listed Sponsors

collaborator

Spanish Breast Cancer Research Group

OTHER

lead

ITF Research Pharma, S.L.U.

INDUSTRY